{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:31:05Z","timestamp":1785864665169,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glecaprevir is a substrate for organic anion-transporting polypeptide (OATP) 1B1\/1B3, which transports bilirubin. Hyperbilirubinemia is an adverse event during anti-hepatitis C virus treatment with glecaprevir and pibrentasvir. Gadoxetic acid is also transported by OATP1B1\/1B3, and we aimed to evaluate whether gadoxetic acid-enhanced magnetic resonance (MR) imaging was associated with glecaprevir trough concentrations (C<jats:sub>trough<\/jats:sub>). We further determined whether this was predictive of hyperbilirubinemia development in a cohort of 33 patients. The contrast enhancement index (CEI), a measure of hepatic enhancement effect on the hepatobiliary image, was assessed. Glecaprevir C<jats:sub>trough<\/jats:sub> was determined 7\u00a0days after administration. Five of the 33 patients (15%) developed Common Terminology Criteria for Adverse Events grade\u2009\u2265\u20092 hyperbilirubinemia. We found a negative relationship between CEI and C<jats:sub>trough<\/jats:sub> (r\u2009=\u2009\u2212\u20090.726, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The partial correlation coefficient between CEI and C<jats:sub>trough<\/jats:sub> was\u2009\u2212\u20090.654 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while excluding the effects of albumin, FIB-4 index, and indirect bilirubin at baseline. The C<jats:sub>trough<\/jats:sub> was significantly higher in patients with hyperbilirubinemia than in those without (<jats:italic>p<\/jats:italic>\u2009=\u20090.008). In multivariate analysis, CEI\u2009\u2264\u20091.71 was an independent factor influencing the development of hyperbilirubinemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.046). Our findings indicate that gadoxetic acid MR imaging can help predict glecaprevir concentration and development of hyperbilirubinemia.<\/jats:p>","DOI":"10.1038\/s41598-022-11707-6","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T12:16:37Z","timestamp":1652357797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Hironao","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Nakadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ikejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"11707_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad, F. et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66, 389\u2013397. https:\/\/doi.org\/10.1002\/hep.29081 (2017).","journal-title":"Hepatology"},{"key":"11707_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns, X. et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 17, 1062\u20131068. https:\/\/doi.org\/10.1016\/S1473-3099(17)30496-6 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"11707_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12072-020-10019-z","volume":"14","author":"A Nozaki","year":"2020","unstructured":"Nozaki, A. et al. The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: A comprehensive analysis of a prospective multicenter study. Hepatol. Int. 14, 225\u2013238. https:\/\/doi.org\/10.1007\/s12072-020-10019-z (2020).","journal-title":"Hepatol. Int."},{"key":"11707_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/jcph.959","volume":"57","author":"CW Lin","year":"2017","unstructured":"Lin, C. W. et al. Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy white, Chinese, and Japanese adult subjects. J. Clin. Pharmacol. 57, 1616\u20131624. https:\/\/doi.org\/10.1002\/jcph.959 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"11707_CR5","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1074\/jbc.M004968200","volume":"276","author":"Y Cui","year":"2001","unstructured":"Cui, Y., K\u00f6nig, J., Leier, I., Buchholz, U. & Keppler, D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276, 9626\u20139630. https:\/\/doi.org\/10.1074\/jbc.M004968200 (2001).","journal-title":"J. Biol. Chem."},{"key":"11707_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/00498254.2013.820006","volume":"44","author":"WJ Chiou","year":"2014","unstructured":"Chiou, W. J. et al. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44, 276\u2013282. https:\/\/doi.org\/10.3109\/00498254.2013.820006 (2014).","journal-title":"Xenobiotica"},{"key":"11707_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00228-018-2576-4","volume":"75","author":"MP Kosloski","year":"2019","unstructured":"Kosloski, M. P. et al. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. Eur. J. Clin. Pharmacol. 75, 217\u2013226. https:\/\/doi.org\/10.1007\/s00228-018-2576-4 (2019).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"11707_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017343","volume":"98","author":"JH Yoon","year":"2019","unstructured":"Yoon, J. H. et al. A case report of glecaprevir\/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 98, e17343. https:\/\/doi.org\/10.1097\/MD.0000000000017343 (2019).","journal-title":"Medicine (Baltimore)"},{"key":"11707_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jcph.811","volume":"57","author":"H Okubo","year":"2017","unstructured":"Okubo, H. et al. Gadoxetic acid-enhanced MR imaging predicts simeprevir-induced hyperbilirubinemia during hepatitis C virus treatment: A pilot study. J. Clin. Pharmacol. 57, 369\u2013375. https:\/\/doi.org\/10.1002\/jcph.811 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"11707_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196747","volume":"13","author":"H Okubo","year":"2018","unstructured":"Okubo, H. et al. Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. PLoS\u00a0One 13, e0196747. https:\/\/doi.org\/10.1371\/journal.pone.0196747 (2018).","journal-title":"PLoS\u00a0One"},{"key":"11707_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/liv.14829","volume":"41","author":"H Wedemeyer","year":"2021","unstructured":"Wedemeyer, H. et al. Glecaprevir\/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. Liver Int. 41, 949\u2013955. https:\/\/doi.org\/10.1111\/liv.14829 (2021).","journal-title":"Liver Int."},{"key":"11707_CR12","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1038\/s41598-021-93095-x","volume":"11","author":"KC Chang","year":"2021","unstructured":"Chang, K. C. et al. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci. Rep. 11, 13543. https:\/\/doi.org\/10.1038\/s41598-021-93095-x (2021).","journal-title":"Sci. Rep."},{"key":"11707_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","volume":"150","author":"SD Campbell","year":"2004","unstructured":"Campbell, S. D., de Morais, S. M. & Xu, J. J. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150, 179\u2013187. https:\/\/doi.org\/10.1016\/j.cbi.2004.08.008 (2004).","journal-title":"Chem. Biol. Interact."},{"key":"11707_CR14","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1124\/dmd.110.032862","volume":"38","author":"M Leonhardt","year":"2010","unstructured":"Leonhardt, M. et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: Role of human organic anion transporters. Drug. Metab. Dispos. 38, 1024\u20131028. https:\/\/doi.org\/10.1124\/dmd.110.032862 (2010).","journal-title":"Drug. Metab. Dispos."},{"key":"11707_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2133\/dmpk.25.190","volume":"25","author":"K Ogasawara","year":"2010","unstructured":"Ogasawara, K. et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet. 25, 190\u2013199. https:\/\/doi.org\/10.2133\/dmpk.25.190 (2010).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"11707_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 69, 461\u2013511. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026 (2018).","journal-title":"J. Hepatol."},{"key":"11707_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/jmri.23758","volume":"36","author":"S Goshima","year":"2012","unstructured":"Goshima, S. et al. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J. Magn. Reson. Imaging 36, 1148\u20131153. https:\/\/doi.org\/10.1002\/jmri.23758 (2012).","journal-title":"J. Magn. Reson. Imaging"},{"key":"11707_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1148\/radiol.11100586","volume":"260","author":"A Yamada","year":"2011","unstructured":"Yamada, A. et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260, 727\u2013733. https:\/\/doi.org\/10.1148\/radiol.11100586 (2011).","journal-title":"Radiology"},{"key":"11707_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1872-034X.2012.01027.x","volume":"42","author":"K Kumazawa","year":"2012","unstructured":"Kumazawa, K., Edamoto, Y., Yanase, M. & Nakayama, T. Liver analysis using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: Correlation with histological grading and quantitative liver evaluation prior to hepatectomy. Hepatol. Res. 42, 1081\u20131088. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.01027.x (2012).","journal-title":"Hepatol. Res."},{"key":"11707_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/jmri.25518","volume":"45","author":"A Ba-Ssalamah","year":"2017","unstructured":"Ba-Ssalamah, A. et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?. J. Magn. Reson. Imaging 45, 646\u2013659. https:\/\/doi.org\/10.1002\/jmri.25518 (2017).","journal-title":"J. Magn. Reson. Imaging"},{"key":"11707_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2217\/pgs.13.132","volume":"14","author":"H Okubo","year":"2013","unstructured":"Okubo, H. et al. Polymorphisms in the organic anion transporting polypeptide genes influence liver parenchymal enhancement in gadoxetic acid-enhanced MRI. Pharmacogenomics 14, 1573\u20131582. https:\/\/doi.org\/10.2217\/pgs.13.132 (2013).","journal-title":"Pharmacogenomics"},{"key":"11707_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1124\/mol.115.100578","volume":"88","author":"Y Matsuzaka","year":"2015","unstructured":"Matsuzaka, Y., Hayashi, H. & Kusuhara, H. Impaired hepatic uptake by organic anion-transporting polypeptides is associated with hyperbilirubinemia and hypercholanemia in Atp11c mutant mice. Mol. Pharmacol. 88, 1085\u20131092. https:\/\/doi.org\/10.1124\/mol.115.100578 (2015).","journal-title":"Mol. Pharmacol."},{"key":"11707_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1148\/radiol.12112061","volume":"264","author":"A Nassif","year":"2012","unstructured":"Nassif, A. et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264, 741\u2013750. https:\/\/doi.org\/10.1148\/radiol.12112061 (2012).","journal-title":"Radiology"},{"key":"11707_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","volume":"34","author":"B Hagenbuch","year":"2013","unstructured":"Hagenbuch, B. & Stieger, B. The SLCO (former SLC21) superfamily of transporters. Mol. Aspects Med. 34, 396\u2013412. https:\/\/doi.org\/10.1016\/j.mam.2012.10.009 (2013).","journal-title":"Mol. Aspects Med."},{"key":"11707_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1159\/000343092","volume":"30","author":"KE Bae","year":"2012","unstructured":"Bae, K. E. et al. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig. Dis. 30, 617\u2013622. https:\/\/doi.org\/10.1159\/000343092 (2012).","journal-title":"Dig. Dis."},{"issue":"2176","key":"11707_CR26","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.ejrad.2013.08.021","volume":"82","author":"A Cieszanowski","year":"2013","unstructured":"Cieszanowski, A. et al. Detection of active bile leak with Gd-EOB-DTPA enhanced MR cholangiography: Comparison of 20\u201325 min delayed and 60\u2013180 min delayed images. Eur J. Radiol. 82(2176), 2182. https:\/\/doi.org\/10.1016\/j.ejrad.2013.08.021 (2013).","journal-title":"Eur J. Radiol."},{"key":"11707_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchromb.2014.02.028","volume":"958","author":"I Vanwelkenhuysen","year":"2014","unstructured":"Vanwelkenhuysen, I., de Vries, R., Timmerman, P. & Verhaeghe, T. Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 958, 43\u201347. https:\/\/doi.org\/10.1016\/j.jchromb.2014.02.028 (2014).","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life Sci."},{"key":"11707_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1148\/radiol.10100621","volume":"259","author":"H Watanabe","year":"2011","unstructured":"Watanabe, H. et al. Staging hepatic fibrosis: Comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 259, 142\u2013150. https:\/\/doi.org\/10.1148\/radiol.10100621 (2011).","journal-title":"Radiology"},{"key":"11707_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.5754\/hge13291","volume":"60","author":"H Okubo","year":"2013","unstructured":"Okubo, H. et al. Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences. Hepatogastroenterology 60, 1547\u20131551. https:\/\/doi.org\/10.5754\/hge13291 (2013).","journal-title":"Hepatogastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11707-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:43:40Z","timestamp":1669344220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11707-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11707"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11707-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"9 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Okubo H and Atsukawa M received lecture fees and a research grant from AbbVie. All remaining authors declare that they have no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7847"}}